MAINRITSAN3 RCT, RTX v PLBO in AAV 28mo relapse free survival ⬇️ RTX (96% vs 74%, NNT~4), majr (100% vs 87%, NNT~8) 1. Selected grp (all pts from MAINRITSAN2) 2. All pts had GC q3mos - IRL benefit could be bigger? Strong data for RTX >2yrs in AAV PDF: https://t.co/Mbrq7bFHk0 https://t.co/auKJ3QPKr0

• Articles I Have Tweeted About - Organized by Date - Google Drive

Drug retention rates & treatment outcomes in 1,860 axSpA patients Rx with secukinumab in routine clinical practice in 13 European countries in the EuroSpA research collaboration network -> registry data drug retention rates THU0398 @RheumNow #EULAR2020 https://t.co/x3Y4tMetij https://t.co/DkUyIfyWwS

• EULAR Abstract Archive

And another one! No association of MTX with worsening of ILD in this study by Men-Vazquez et al. #EULAR2020 https://t.co/X7C6KyC29L

Enticing stuff. Avacopan wins on 52w remission, steroid toxicity/use, renal fx, with minimal toxicity. Looks good to be a steroid replacement in AAV, with real benefit for patients. Exciting but cost will dictate if we get to use it (see: apremilast) OP0011 #EULAR2020 @RheumNow https://t.co/WTFk21D0KY

#EULAR2020 ABST#OP0012 German RABBIT registry show TNFi has less risk for venothrombolic events HR 0.53 (95% CI 0.33-0.86) compared to csDMARD in RA. Age > 65 years, CRP > 5 mg/L increases risk for VTE, no differences with steroids or smoking status. @RheumNow https://t.co/Hkv6T7pl9f

#EULAR2020 ABST#OP0014 Plenary session: Secukinumab and etanercept do NOT work for anterior uveitis in SpA based on Swedish Rheum Quality Registry of > 2600 patients @rheumnow https://t.co/2kJ3b4JObq

#EULAR2020 Abstr#LB001 Coming soon...another indication for @Rinvoq? Favorable response in phase III trial of upadacitinib vs. ADA vs. PCB for PsA (SELECT-PsA-1) @abbvie @rheumnow https://t.co/0udmPlR2pQ

#EULAR2020 OP0020: RABBIT 5500 pt study of all DMARDS/biologics, IL-6 inh may be the best to improve fatigue seen in RA patients @rheumnow https://t.co/VJW8MwMamM

#EULAR2020 Prof. T Domer: baricitinib show promise in phase II trial for SLE: Microarray analysis noted reduction in IFN signature; however, the reduction did not correlate w/SLEDAI-2K or SRI4 clinical response @RheumNow https://t.co/cW4egzSnAs

#EULAR2020 OP0160 Prospective study of Hopkins Lupus Cohort: HCQ blood levels can predict risk for thrombotic events in SLE. Dr. M Petri advocates this is another reason for monitoring HCQ whole blood levels. Goal HCQ whole blood level should be 1000-1500 ng/mL @rheumnow https://t.co/mM6jsJ2Qmf

This Spanish study of 255 SpA pts found that acute unilateral anterior uveitis was the most common pattern, primarily in HLA B27+. NO difference in incidence between SEC and TNFi treated pts. #EULAR2020 @RheumNow Poster #THU0388 https://t.co/OMfG8atfE4

Interesting observation: obese patients seem to respond better to etanercept than to mAb TNFi @RheumNow https://t.co/WrjwE4jUNI

• https://twitter.com/pkiely500/status/1268871993539072001

Our study shows that HCQ retinopathy virtually never occurs in first 5 yrs, SLE has more risk than other diseases such as RA and chloroquine has a far higher risk of retinal toxicity OP0333 #EULAR2020 @RheumNow @CRASCRRheum @earlyarthritis https://t.co/ZzRy3po4yw

• https://twitter.com/kdao2011/status/1268532437275025409

#EULAR2020 OP0167 Results are finally in!! MMF can be safely w/drawn in quiescent SLE: prospect RCT (nonblinded) 102 pts. MMF tapered over 12 weeks, f/u 60 weeks; no sig diff for flares in pts who stopped MMF vs. maintained; pts who cont MMF had ⬆️ minor infections. @rheumnow https://t.co/bOnuEBLis9

When starting IV Pegloticase in #Gout, Do you start a DMARD too? #EULAR2020